Using AR+ LNCaP cells as a prostate cancer (PCa) model, Torin2 (Figure S8F) and XAV939 (Figure S8G) treatment for 3 days disturbed the expression of 10 and 6 out of 12 integrin genes, respectively. This evidence concerns the gene AR and prostate cancer.